Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RORA | P35398 | 1/20 | 0.37 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12506514 | 0.94 | METTL3 (0.45) | METTL3MAPTPDE10ATP53GAA | |
| SCHEMBL1300493 | 0.90 | METTL3 (0.57) | METTL3MAPTPDE10AKDM4ETSHR | |
| SCHEMBL1300490 | 0.90 | METTL3 (0.57) | METTL3MAPTPDE10AKDM4ETSHR | |
| SCHEMBL12110646 | 0.88 | METTL3 (0.38) | METTL3MAPTPDE4BPDE10AKDM4E | |
| SCHEMBL12110424 | 0.85 | KCNQ3 (0.42) | METTL3MAPTPDE4BKDM4ENPC1 | |
| SCHEMBL12110612 | 0.81 | PDE4B (0.42) | MAPTPDE4BNPC1TSHRTP53 | |
| SCHEMBL1301595 | 0.80 | METTL3 (0.57) | METTL3PDE10AKDM4EGAA | |
| SCHEMBL1301599 | 0.80 | METTL3 (0.57) | METTL3PDE10AKDM4EGAA | |
| SCHEMBL12505033 | 0.80 | METTL3 (0.48) | METTL3MAPTKDM4EGAAKMT2A | |
| SCHEMBL12504041 | 0.79 | MAPT (0.44) | METTL3MAPTPDE10ATSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885MAPT 3259/4885PDE4B 1082/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885MAPT 3259/4885PDE4B 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.